HLA-C and neoplasm: Low-dose decitabine is reported to increase the expression of MHC and cytokines, and improve lymphocyte infiltration into tumor sites, thereby enhancing the efficiency of PD-1 blockade in CRC with microsatellite stability by re-modulating the TME (143).